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Abstract
A disorder of copper metabolism at Wilson’s disease (WD), conditioned by a mutation of adenosine thriphospate P-type 
gene (ATP7B), results in irreversible changes in the liver and in the nervous system. Mortality is high at WD, but it is one of hered-
itary diseases, well subjected to the therapy. The disease is manifested in the early age, but its clinical course in children is symp-
tomless that essentially complicates diagnostics. A single reliable method is genetic analysis for revealing mutations in ATP7B gene. 
The aim of the work was to analyze clinical manifestations and course of Wilson’s disease cases, genetically verified in chil-
dren by detecting mutations of ATP7B gene. 
The research group included children of 6–17 years old with different injury degrees of the hepatobiliary system. According 
to results of the molecular-genetic analysis, the most spread allele variant of ATP7B gene (H1069Q) in Europe was confirmed in 
10 patients of child age, including 4 cases of homozygosity. 
In 10 cases of the confirmed diagnosis of Wilson’s disease in child age in 100 % (in all 10) of persons, a clinical manifestation 
was characterized by disorders from the hepatobiliary system, and only in 1 (10 %) – changes from the nervous system. At raising 
the level of transaminase in children, even at the normal bilirubin level and negative tests for viral hepatitis, it is recommended to 
carry out genetic testing for Wilson’s disease.




Wilson’s disease (WD), in the Russian literature – Wilson’s-Konovalov or hepatocerebral 
dystrophy, – is a chronic hereditary disease with the autosomal-recessive inheritance, connected 
with disorders of hepatocellular copper metabolism, conditioned by the dysfunction of copper- 
binding AT-phase of P-type, coded by ATP7B gene [1]. 
According to the conducted meta-analysis of genetic studies, the prevalence of WD is 13.9 
for 100 000, or 1 for 7194 [2] whereas the frequency of heterozygous carriage of mutations in ATP7B 
gene is 1 for 90–150 persons, although this pathology was earlier considered essentially rarer (1:30–
50 000). Ukraine doesn’t have a united register of WD cases. WD is caused by the mutation of ade-
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nosine thriphosphate P-type gene (ATP7B) that is in chromosome 13q14. 3 and consists of 21 exons 
and 20 introns. The copper-binding AT-phase, coded by ATP7B gene is a group of transmembrane 
transport proteins of copper, mediating its metabolism. For the present, 600 pathogenic mutations are 
revealed in ATP7B gene, and new ones are continuously found throughout the world [3, 4]. 
Wilson’s disease is characterized by the high mortality, but it is one of hereditary diseases, 
well subjected to the therapy. Irreversible changes in tissues may be prevented at early diagnostics 
and treatment [5]. Initial stages of the disease are characterized with changes from functional he-
patic samples, general weakness and appetite decrease. At later stages neurological changes join, 
heavier hepatic manifestations develop (chronic hepatitis, liver cirrhosis), and Kayser-Fleischer 
ring appears on the descemet membrane of the cornea [6–8]. Many cases of Wilson’s disease are 
not diagnosed, because patients are observed for other diagnoses [6, 8].
Taking into account the progressive clinical course of Wilson’s disease and possibilities 
of the effective therapy, an urgent problem is its early diagnostics, already in child age. There 
is no direct test for diagnosing Wilson’s disease except genetic diagnostics, but the low level of 
ceruloplasmin and copper in blood, and also amount of copper, removed with urine for 24 hours 
(higher 100 mcg/24 hours (1.6 mcmol/24 hours), together allow to make a conclusion about a cop-
per amount in the organism, but we must remember that the high copper level in urine is not a 
pathognomonic sign of Wilson’s disease, but this phenomenon is also observed at autoimmune 
hepatitis and cholestasis [9, 10]. 
Most patients demonstrated the light form of liver dysfunction, confirmed by the biochem-
ical study by the increased level of bilirubin in blood, high activity of aspartate aminotransferase 
and alanine aminotransferase. At hard liver lesions, there can be observed the decreased albumin 
level. Despite the fact, that first symptoms appear in childhood, it is difficult to diagnose Wilson’s 
disease at early stages. The clinical course in children is symptomless, and diagnostic criteria, es-
tablished for adults [11], not always fit. 
Only revelation of two mutations in ATP7B gene allows to confirm the diagnosis of Wilson’s 
disease genetically and to attribute 4 points by the point system WD (8 th International Meeting on 
Wilson’s’s disease, Leipzig 2001) to a patient [12]. 
According to the point system, all diagnostic criteria allow to reveal the disease, when the 
organism have already undergone serious lesions, fixed in changes of biochemical parameters of 
blood, just the increase of transminase (АLТ, АSТ) levels, increase of the level of alkaline phos-
phatase, total bilirubin, copper level of blood serum and of daily urine, decrease of ceruloplasmin, 
appearance of Kayser-Fleischer ring (or its germs) on the eye cornea and other non-specific mani-
festations, such as aminociduria, nephrocalcinosis, cardiomyopathy and so on [13–15]
The diagnostic of Wilson’s disease in child age often remains a clinical finding, but it must 
be accented, that the genetic defect is present from the moment of conception and influences the 
work of systems and organs. The timely involvement of therapeutic arrangements, directed on re-
moval of excessive copper from the patient’s organism, may essentially improve the life quality and 
duration of this contingent of patients. 
The aim of the work was to analyze clinical manifestations and course of Wilson’s disease cases, 
genetically verified in children by detecting mutations of ATP7B gene for improving its diagnostics. 
2. Materials and methods 
The material of the study was DNA of 25 children, 6–17 years old (14 boys and 11 girls), 
with clinical or biochemical manifestations, typical for Wilson’s disease. Viral hepatitis, alcoholic 
cirrhosis, medicamentous lesion of the liver were excluded for all patients of the experimental 
group. Patients with neurological manifestations were selected by the method of genealogy anal-
ysis, and persons with disease manifestations in each generation that didn’t prove the hereditary 
type of a sign or autosomal-recessive type of inheritance were excluded. There were taken regis-
tration cards, including information about age, gender, clinical manifestations and data of labora-
tory studies (biochemical indices of blood and urine, MRT data of brain of patients). The material 
for the study was taken after singing an informed consent and permission for DNA storage at a 
bank by parents. For taking a sample of DNA, there were used leukocytes of peripheral blood, 
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washed in 2–5 ml of venous blood by the method of enzymatic disintegration with K proteinase 
and further salting out [26]. The analysis of H1069Q mutation of ATP7B gene was carried out by 
PCR BI-PASA method. There were used two pairs of primers: external pair F-5’ GGG CAG 
CTA GGA GAG AAG GAC 3’, R-5’ AGT TCT GCC TCA GGA GTG TGA CT 3’, internal pair: 
F-5’ GGA GGC CAG CAG TGA ACA A 3’, R-5’ GAC TGC CAC GCC CAA GGG G 3’, 2xGreen 
master mix (ThermoScientific), in the automatic regime on the Thermocycler T-CY (Crea-Technol-
ogy) with the following temperature parameters: 1 – 95 °С 5 min, 2 – 94 °С 1 min, 3 – 30 cycles 
54° 30 s, 72 °С 25 s [28]. Electrophoresis was carried out in 2 % agarose gel. The presence of a frag-
ment of 212 pairs of bases testifies to the absence of H1069Q mutation. The presence of a fragment 
of 181 pair of bases testifies to the presence of H1069Q mutation in the homozygous condition. Two 
fragments of 212 and 181 pairs of bases testify to the mutation in the heterozygous condition [24]. 
There was carried out the HRM analysis (high resolution melting) of exons 8 and 14 as to screening 
the presence of other allele variants. The obtained meting curves of persons from the experimental 
group were considered with ones of healthy persons, looking for differences in melting tempera-
tures of DNA fragments. Differences in melting temperatures testify to the presence of different 
nucleotides in same gene locus. Samples with changed melting curves were further sequenced. 5 of 
25 children with the high risk of Wilson’s disease (with 3 points by the point scale) underwent the 
compete sequencing of ATP7B gene at the base of Riga Stradins University. The primary sequence 
of DNA was realized by Senger’s method. The analysis of obtained sequence diagrams was carried 
out in the program Chromas, UGENE. The multiplied leveling was realized in the program Muscle, 
pathogenicity was estimated by Mutation tester, Provean internet resources. 
3. Results of genetic testing of mutations of ATP7B gene and clinical characteristic of chil-
dren with suspected Wilson’s disease 
DNA extraction and molecular-genetic studies of gene mutations were realized at the base 
of the laboratory of genetic studies of SI «IHP NAMS of Ukraine». Patients were directed for ob-
servation from different regions of Ukraine, namely Lviv (8 persons), Zaporizhzhya (8 persons), 
Dnipro (3 persons), Rivne (3 persons), Khmelnytsky (2 persons) and Donetsk (1 person). 
Nine (5 boys and 4 girls) of 25 children were homo- or heterozygous for mutation H1069Q 
of ATP7B gene. According to the results of the molecular-genetic analysis, the pathogenic variant of 
ATP7B p.His1069Q gene (at the level of cDNA c. 3207C>A), most spread in Europe, was confirmed 
in 9 child patients, including 4 cases of homozygosity. In one case H1069Q mutation was revealed 
with another allele variant of ATP7B gene. The genetic diagnostic results of mutations of ATP7B 
gene among child patients with Wilson’s-Konovalov disease are presented in Table 1. 
Table 1
Results of genetic diagnostic of mutations of ATP7B gene among children with non-specific lesions of 
hepatobiliary system and suspected Wilson’s-Konovalov disease 
Genotype of ATP7B gene
Frequency 
N (%)
c. 3207C>A/3207C>A 4 (16)
c. 3207C>A/N 3 (12)
c. 3207C>A/2304dupC 1 (4)




The results of ATP7B gene mutations testing among children with non-specific lesions of 
the hepatobiliary system, presented in Table 1, testify that the diagnosis of Wilson’s disease was 
confirmed in 9 of 25 persons that are 36 % because even at revealing one mutation in ATP7B 
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gene together with biochemical indicators, a patient takes 4 points by the point scale. One of pa-
tients didn’t demonstrate any mutation in the coding sequence of ATP7B gene, but the totality of 
biocemical indicators (copper in urine 227 mcg/day, ALT – 1745 IU/l, АSТ – 873 IU/l, bilirubin 
314 mcMol/l) and clinical signs (liver cirrhosis, focal changes in the brain) and positive answer to 
the pathogenic therapy inclined to the Wilson’s disease diagnosis. In this case a mutation in intron 
parts of the gene, not sequenced in this cohort of patients, are possible. 
The obtained results demonstrated that the study of H1069Q major mutation of ATP7B gene 
is highly effective, and even revelation of this mutation in one allele is diagnostically significant at 
presence of minimal clinical changes and adds 1 point at the point diagnostic estimation. 
The analysis of clinical manifestations of WD in children at the moment of genetic diagnos-
tic was realized. The results are presented in Table 2.
Table 2 
Clinical manifestation of the disease among children with the verified diagnosis of Wilson’s disease 
Sample 
number Genotype Gender 





tobiliary system Biochemical indices
1 c. 3207C>A/c2304dupC m 10 Absent Liver cirrhosis 
Ceruloplasmin 0.1 g/l (norm: 
0.2–0.6 g/l), copper in blood 
33 mcg/dl (norm: 80–160 mcg/l). 
Copper in urine – 961 mg/day, 
АSТ – 70 IU/l, АLТ – 164 IU/l, 
bilirubin 12.4 mcMol/l
2 c. 3207C>A/3207C>A m 17 Absent Autoimmune hepatitis 
3 c. 3207C>A/3207C>A f 14 Absent Autoimmune hepatitis 
4 c. 3207C>A/X m 12 Absent Fulminant hep-atitis 
5 c. 3207C>A/X f 14 Absent Liver cirrhosis 
Copper in urine 1025 mg/day, 
ceruloplasmin 0,12 g/l,  
АLТ – 64 IU/l, АSТ – 115 IU/l, 
bilirubin 25.8 mcMol/l
6 c. 3207C>A/3207C>A m 6 Absent Autoimmune hepatitis 
7 c. 3207C>A/X m 6 Absent Autoimmune hepatitis 
8 c. 3207C>A/3207C>A f 7 Absent chronic  hepatitis
Copper in urine 175 mg/day,  
ceruloplasmin 0.14 g/l,  
АLТ – 118 IU/l, АSТ – 88 IU/l,  
bilirubin 7.5 mcMol/l 
9 с.3402delC/Х f 13 absent Liver cirrhosis/he-molytic anemia 
Copper in urine 1700 mg/day, 
ceruloplasmin less 0.03 g/l,  
АLТ – 86 IU/l, АSТ – 112 IU/l, 
bilirubin 53 mcMol/l 
10 Х\Х m 16 Focal changes in the brain bridge Liver cirrhosis 
Copper in urine 227 mcg/day, 
АLТ – 1745 IU/l, АSТ – 873 IU/l, 
bilirubin 314 mcMol/l 
In a half of confirmed WD cases, the clinical diagnosis was autoimmune hepatitis that, as 
we assume, indicated only on exclusion of other known factors of hepatobiliary disorders, but not 
the presence of immune reactions. The obtained results indicate the fact that at child age cases of 
Wilson’s disease can be treated and observed as other diagnoses (namely, autoimmune hepatitis), 
if a doctor has no suspect about WD and doesn’t direct patients to the correspondent examination. 
It is necessary to pay attention, that among children with diagnosed WD of even teen age, 
there are no manifestations from the nervous system, excluding one case. None of the diagnosed 
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patients with WD in child age demonstrated Kayser-Flescher rings on the cornea membrane. So, 
the approach, when at fixing copper metabolism disorders, the examination of an oculist is referent, 
is ineffective in all cases, described in the work. 
4. Discussion of the obtained results of testing ATP7B gene mutation and clinical character-
istic of children with suspected Wilson’s disease 
The genetic testing of ATP7B gene is carried out one time and allows to reveal the disease before 
clinical signs appeared that is important for timely treatment and prevention of heavy lesions of the 
liver and neurological changes. Some mutations demonstrate the regional and ethnic difference. Among 
Europeans, the most spread mutation is p. His1069Gln (14 exon), whereas in Asia – p. Arg778Leu 
(8 exon) [27], and in Brazil – p. His1069Gln and 3402delC in exon 15 [21, 27]. For the studied sample, 
it is informative to analyze H1069Q mutation. Such analysis is available and may be used for both 
confirmation and exclusion of this disease and need wider prescription. We also predict higher fre-
quency of this nosology in Ukraine and its hypo diagnostics. The previously established frequency 
of heterozygous carriers of H1069Q mutation of ATP7B gene is 1 for 58 that is higher than in other 
populations [23, 24]. The frequency of Wilson’s disease heterozygous carriers, taking into account 
other mutations, may reach 1 for 40, so the disease occurrence is 1 for 6500. Taking into account the 
population size, 4–6 cases must be diagnosed in the Lviv region only, and near 350 must be observed, 
among which 50–90 persons of child age. Unfortunately, statistical data of this nosology are limited. 
The genetic defect of a patient is present from birth, but this disease is mainly diagnosed 
already in adult age.
During three years, Wilson’s disease in child age was confirmed in 10 persons of 25 sus-
pected, mainly in the second life decade. Three children were younger 10 years. These data testify 
to the necessity for pediatricians to be more careful as to the diagnostic of this disease. All children 
demonstrated liver lesions that varied from cryptogenic hepatitis to cirrhosis and also different vari-
ations of growing transaminase level in blood serum. We find expedient to carry out the differential 
diagnostics and genetic testing of major mutations of ATP7B gene in all cases of idiopathic hepatitis. 
According to ESPGHAN recommendations of 2018, Wilson’s disease must be taken into 
account with the high verification degree (class А) in the differential diagnostics in children, older 
1 year with signs of hepatic illness, starting from the symptomless growth of transaminase up to 
cirrhosis with hepatosplenomegaly and ascites or acute hepatic failure [2]. 
Thus, WD may be diagnosed in different ages, including child one. Among all cases, verified 
at SI “Institute of Hereditary Pathology of NAMSU”, less than one third was diagnosed in child age. 
According to the obtained results, WD is manifested in the young school age (6–7 years), but manifes-
tations are non-specific, related to lesions of the hepatobiliary system of unexplained genesis. 
The sample doesn’t include children with idiopathic cognitive or psychiatric disorders, but 
the literature presents cases, when the first symptom of the disease was behavioral changes, ex-
plained by the pubertal period. That is why Wilson’s disease must be also excluded in teenagers 
with unknown cognitive, psychiatric or motor disorders. 
According to ESPGHAN recommendations, the diagnostic testing must also include serum 
transaminase, total bilirubin, alkaline phosphatase, prothrombin time, ceruloplasmin and daily 
urine by the copper content. 
Ferenzi’s evaluation system is recommended for using for diagnosing Wilson’s disease in child 
age, and it is accented, that the analysis of ATP7B gene mutations facilitates the diagnostics [10]. 
In a case of revealing WD it is recommended to carry out the medical-genetic consulting 
and study of mutations in proband’s relatives, because the disease is inherited by the autosomal-re-
cessive type that is equally spread among males and females. The revelation of mutations in a 
proband also testifies to the fact that both parents are carriers of one of mutations and the risk of 
ill child birth is 25 %. During the period of our work we revealed sibs with homozygous H1069Q 
mutation. At the moment of genetic diagnostic any clinical signs of the disease were present. 
After confirming the diagnosis in a proband, Wilson’s disease must be looked for in first de-
gree relatives. There is information about cases of diagnosing Wilson’s disease at the symptomless 
clinical course in relatives of ill children [11, 12, 25]. 
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None patients in our study demonstrated expressed neurological signs at disease manifesta-
tion. It may be explained by the fact that the excessive copper accumulation in first turn takes place 
in the liver as its main depot, starting from the breast age, when the ration is enriched with food 
products, containing this microelement. When the copper overload continues to grow, it accumulates 
in other organs, such as brain, kidney, spleen, heart, eye cornea. At the absence of diagnostics and 
adequate therapy, cirrhosis, hepatic failure and irreversible changes in the brain take place [2, 5, 21]. 
Taking into account that none diagnosed patients with WD demonstrated Kayser-Fleischer 
rings on the cornea membrane in child age, the referent oculist’s examination at fixing copper dis-
orders is ineffective. The main test for diagnosing WD in children is results of the genetic analysis 
of ATP7B gene mutations. 
5. Conclusions 
9/25 children (36 %) with clinical manifestations of Wilson’s disease demonstrated major 
mutations of ATP7B gene and genetically verified diagnosis of this monogenic pathology. 
The clinical manifestation in all 10 with the verified diagnosis of Wilson’s disease was 
characterized by disorders of the hepatobiliary system that are 100 %, and only in 1 (10 %) – by 
changes of the nervous system.
For cases of the transaminase level increase in children, even at the normal bilirubin level and 
negative tests for virus’s hepatitis, it is recommended to carry out genetic testing for Wilson’s disease. 
Taking into account the availability of the therapy, it is necessary to raise carefulness of pe-
diatricians, child gastroenterologists and infectious diseases specialists as to diagnosing Wilson’s 
disease in child age. 
Taking into account the wide spectrum of mutations (more than 500); it is necessary to 
establish the list of most often ones for introducing in medical-genetic consulting practice for the 
fast and economically effective diagnostics. Such researches have not been realized in Ukraine 
that is why there is no unambiguous answer about the disease prevalence. We assume that a part 
of revealed cases of WD suspect may have disorders in other not tested gene parts. This work also 
doesn’t exclude the presence of big deletions and duplications that can be also a genetic factor of 
P-type ATPase function disorder in some patients. The work is also limited by the cohort of exam-
ined child patients, namely children, consulted at highly specialized health protection institutions, 
knowing about WD. Taking into account the obtained results, it will be expedient to carry out the 
genetic study in the wide sample of child patients with the diagnosis of autoimmune, cryptogenic 
hepatitis. We don’t exclude that the carefulness as to the needs of excluding WD in children with 
hepatic idiopathic diseases is low at the level of district infectious diseases specialists and gastro-
enterologists. 
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